Osimertinib · Tagrisso

Small molecule

Also known as AZD9291

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (5)
US
  • Locally Advanced, Unresectable (Stage III) EGFR Mutation-Positive NSCLC TAGRISSO is indicated for the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ].
Product first approved 2015Outside this platform's coverageFDA label
CN
  • EGFR T790M mutation-positive metastatic NSCLC after EGFR TKI therapy
Product first approved 2017astrazeneca.com
CA
  • EGFR Mutation-Positive NSCLC Adjuvant Protected B / Protégé B TAGRISSO (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA1 non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (see 14 CLINICAL TRIALS). • A validated test is required to identify EGFR mutation-positive status prior to treatment (see7 WARNINGS AND PRECAUTIONS, Assessment of EGFR Mutation Status). Unresectable Stage III TAGRISSO is indicated for the treatment of patients with...
Product first approved 2016Health Canada
JP
  • EGFR T790M mutation-positive inoperable or recurrent NSCLC
Product first approved 2016astrazeneca.com
EU
  • Locally advanced or metastatic EGFR T790M mutation-positive NSCLC (conditional marketing authorisation)
Product first approved 2016astrazeneca.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (28)
Non-Small Cell Lung Cancer
NCT05120349 · AstraZeneca
2022-02-21 – 2032-11-01 · Non-Small Cell Lung Cancer
What this study did
NCT04351555 · AstraZeneca
2020-12-16 – 2029-06-13 · Non-Small Cell Lung Cancer
What this study did
NCT07376382 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-06-01 – 2029-06-06 · NSCLC
What this study did
NCT06735391 · Shanghai JMT-Bio Inc.
2024-10-23 – 2029-05-30 · Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC, Previously Untreated Systematically NSCLC
What this study did
NCT06323148 · Fudan University
2024-04-01 – 2029-03-31 · Lung Cancer, EGFR Gene Mutation, Minimal Residual Disease
What this study did
NCT06486142 · Region Skane
2022-09-21 – 2028-09 · Non-Small Cell Lung Cancer
What this study did
NCT04695925 · Li Zhang, MD
2021-03-29 – 2027-12-30 · Non-small Cell Carcinoma, EGFR Gene Mutation
What this study did
NCT04765059 · AstraZeneca
2021-09-12 – 2027-06-02 · Non-small Cell Lung Cancer
What this study did
NCT02411448 · Eli Lilly and Company
2015-05-06 – 2026-12 · Metastatic Non-Small Cell Lung Cancer
What this study did
NCT05261399 · AstraZeneca
2022-08-03 – 2026-11-23 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT05015608 · Hutchison Medipharma Limited
2021-11-22 – 2025-08-22 · Non-small Cell Lung Cancer
What this study did
NCT05104281 · Qingdao Central Hospital
2021-01-01 – 2024-12-31 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02454933 · AstraZeneca
2015-07-15 – 2023-06-21 · Locally Advanced or Metastatic EGFR T790M+ NSCLC
What this study did
NCT04816214 · Novartis Pharmaceuticals
2021-09-22 – 2022-12-27 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02972333 · Shandong Cancer Hospital and Institute
2016-12 – 2019-12 · EGFR-TKI Resistant Mutation, Nonsmall Cell Lung Cancer, AZD9291, Brain Metastases
What this study did
NCT02474355 · AstraZeneca
2015-09-18 – 2019-04-18 · Lung Cancer
What this study did
Other / comorbidity
NCT05629234 · AstraZeneca
2023-05-08 – 2027-02-22 · Cancer
What this study did
NCT02997501 · AstraZeneca
2016-12-23 – 2018-10-24 · Lung Cancer
What this study did
Phase 2/3 (5)
Non-Small Cell Lung Cancer
NCT06908772 · Shanghai JMT-Bio Inc.
2025-04-01 – 2030-01-31 · Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
What this study did
NCT05020769 · Sichuan Baili Pharmaceutical Co., Ltd.
2022-01-06 – 2025-12 · Non-small Cell Lung Cancer
What this study did
NCT02959749 · Qingdao Central Hospital
2015-08 – 2017-12-31 · Progression Free Survival
What this study did
Phase 2 (110)
Non-Small Cell Lung Cancer
NCT07874490 · NYU Langone Health
2026-10 – 2033-12 · Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
What this study did
NCT07329322 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2026-03-30 – 2032-10-31 · Non-Small Cell Lung Cancer
What this study did
NCT07256509 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2025-11-30 – 2032-06-30 · Non-Small Cell Lung Cancer
What this study did
NCT07073365 · Pusan National University Hospital
2025-07-01 – 2031-06-30 · Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor
What this study did
NCT07710612 · Abbisko Therapeutics Co, Ltd
2026-08-31 – 2030-12-31 · Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
What this study did
NCT06206850 · Jair Bar, M.D., Ph.D.
2024-02-19 – 2030-01-01 · Non-squamous NSCLC
What this study did
NCT07622186 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2026-07-15 – 2029-12-31 · Non-Small Cell Lung Cancer
What this study did
NCT07911449 · Cho Ray Hospital
2026-02-27 – 2029-12-31 · Non-Small Cell Lung Cancer, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), EGFR Activating Mutation
What this study did
NCT06436144 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
2024-06 – 2029-12 · Non Small Cell Lung Cancer, EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
What this study did
NCT05526755 · AstraZeneca
2023-03-06 – 2029-11-22 · Stage II-IIIB Non-small Cell Lung Carcinoma
What this study did
NCT05686434 · Tianjin Medical University Cancer Institute and Hospital
2022-10-14 – 2029-10-14 · NSCLC, Stage I
What this study did
NCT05546866 · AstraZeneca
2023-02-09 – 2029-06-30 · Non-small Cell Lung Cancer
What this study did
NCT07669779 · Akeso
2026-07-10 – 2029-05-30 · Advanced Non Small Cell Lung Cancer (NSCLC)
What this study did
NCT07295821 · AstraZeneca
2026-04-01 – 2029-05-30 · Lung Cancer
What this study did
NCT07058519 · Shanghai Chest Hospital
2025-09-23 – 2029-01-24 · Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT07505173 · Tianjin Medical University Cancer Institute and Hospital
2026-01-01 – 2029-01-01 · Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
What this study did
NCT07375316 · Guangdong Association of Clinical Trials
2025-12-15 – 2028-12-30 · Non Small Cell Lung Cancer
What this study did
NCT07603791 · Shanghai Allink Biotherapeutics Co., Ltd.
2026-06-30 – 2028-12-30 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT03586453 · Dana-Farber Cancer Institute
2018-08-13 – 2028-09-01 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT05011487 · Sun Yat-sen University
2021-08-13 – 2028-09 · Non-Small Cell Lung Cancer
What this study did
NCT06827145 · National Cancer Center, China
2024-10-14 – 2028-09 · Non-Small-Cell Lung Cancer
What this study did
NCT05816252 · Klus Pharma Inc.
2023-04-19 – 2028-08-31 · Non-small Cell Lung Cancer
What this study did
NCT06142617 · Peking Union Medical College Hospital
2023-12-01 – 2028-06-30 · Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation
What this study did
NCT05642572 · SWOG Cancer Research Network
2023-05-05 – 2028-06-30 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT07485452 · Maastricht University Medical Center
2026-06 – 2028-06 · Non-Small Cell Lung Cancer
What this study did
NCT05773092 · National Cancer Centre, Singapore
2023-08-01 – 2028-03-31 · NSCLC
What this study did
NCT07323641 · Jonsson Comprehensive Cancer Center
2026-02-19 – 2028-02-01 · Lung Non-Small Cell Carcinoma
What this study did
NCT06918782 · The University of Hong Kong
2025-05-01 – 2027-12-31 · Lung Cancer (NSCLC)
What this study did
NCT03392246 · Dana-Farber Cancer Institute
2018-01-31 – 2027-12-30 · Non-small Cell Lung Cancer
What this study did
NCT04322890 · Hunan Province Tumor Hospital
2020-04-16 – 2027-12-24 · Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation, MET Gene Mutation
What this study did
NCT05528458 · Samsung Medical Center
2022-09-11 – 2027-12-01 · Lung Adenocarcinoma
What this study did
NCT05801029 · AstraZeneca
2023-07-18 – 2027-10-01 · Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT03667820 · University of Texas Southwestern Medical Center
2018-09-26 – 2027-09-30 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT03433469 · University of California, San Francisco
2018-07-31 – 2027-09-30 · Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer
What this study did
NCT06194448 · AstraZeneca
2024-04-21 – 2027-07-07 · Lung Cancer
What this study did
NCT02971501 · National Cancer Institute (NCI)
2018-06-27 – 2027-07-01 · Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
What this study did
NCT05880706 · Sichuan Baili Pharmaceutical Co., Ltd.
2023-07-19 – 2027-07 · Non-small Cell Lung Cancer
What this study did
NCT03191149 · National Cancer Institute (NCI)
2018-04-25 – 2027-06-30 · Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT04335292 · Mark Vincent
2021-01-06 – 2027-06-01 · Non-Small Cell Lung Cancer
What this study did
NCT06498986 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-07-31 – 2027-06 · Non-small Cell Lung Cancer
What this study did
NCT04410796 · Memorial Sloan Kettering Cancer Center
2020-05-28 – 2027-05 · Metastatic Non-small Cell Lung Cancer
What this study did
NCT03410043 · M.D. Anderson Cancer Center
2018-01-17 – 2027-04-01 · Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT03778229 · AstraZeneca
2019-01-09 – 2027-03-31 · Carcinoma
What this study did
NCT04606771 · AstraZeneca
2020-09-28 – 2027-03-15 · Non-Small Cell Lung Cancer
What this study did
NCT06014827 · City of Hope Medical Center
2024-10-21 – 2027-03-09 · Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT05089916 · AIO-Studien-gGmbH
2022-01-20 – 2027-03 · NSCLC, EGFR Positive Non-small Cell Lung Cancer, Oligoprogression
What this study did
NCT03909334 · Xiuning Le
2019-07-25 – 2027-01 · Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer
What this study did
NCT06363734 · Tianjin Medical University Cancer Institute and Hospital
2024-04-09 – 2026-12-31 · Non-small Cell Lung Cancer, EGFR Activating Mutation, Cell Cycle Deregulation, EGFR-TKI Resistant Mutation
What this study did
Phase 1/2 (30)
Non-Small Cell Lung Cancer
NCT04665206 · Vivace Therapeutics, Inc
2021-03-24 – 2030-03-02 · Solid Tumor, Adult, Mesothelioma, NSCLC, Pleural Mesothelioma, Non-Pleural Mesothelioma, Non Small Cell Lung Cancer, Epithelioid Hemangioendothelioma (EHE), Adenoma, Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neoplasms, Mesothelial
What this study did
NCT04743505 · Washington University School of Medicine
2022-01-18 – 2029-12-31 · Metastatic Non Small Cell Lung Cancer
What this study did
NCT07206498 · Wayshine Biopharm, Inc.
2025-10-17 – 2029-10-14 · Non Small Cell Lung Cancer (NSCLC)
What this study did
NCT07486648 · Shanxi Province Cancer Hospital
2026-12-08 – 2029-07-31 · Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell), Advanced Non-small-cell Lung Cancer
What this study did
NCT04486833 · Genprex, Inc.
2021-09-03 – 2029-03 · Carcinoma, Non-Small Cell Lung
What this study did
NCT07535437 · Memorial Sloan Kettering Cancer Center
2026-04-09 – 2028-04 · Non-Small Cell Lung Cancer
What this study did
NCT04285671 · Jonsson Comprehensive Cancer Center
2021-01-29 – 2027-12-02 · Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT03122717 · Dana-Farber Cancer Institute
2017-05-09 – 2027-10 · Non-Small Cell Lung Cancer
What this study did
NCT06109558 · Hunan Province Tumor Hospital
2023-12-31 – 2027-07-30 · Non Small Cell Lung Cancer, RET Gene Mutation, MET Amplification, EGF-R Positive Non-Small Cell Lung Cancer
What this study did
NCT03831932 · National Cancer Institute (NCI)
2020-03-16 – 2027-03-13 · Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT06306456 · Suzhou Genhouse Bio Co., Ltd.
2024-03-05 – 2026-12-31 · Non-Small Cell Lung Cancer With EGFR Mutation
What this study did
NCT03381274 · MedImmune LLC
2018-05-08 – 2026-11-06 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04868877 · Merus B.V.
2021-04-28 – 2026-10-01 · Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
What this study did
NCT05017025 · M.D. Anderson Cancer Center
2022-02-17 – 2026-09-15 · Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT02917993 · Incyte Corporation
2016-12-20 – 2025-12-24 · Lung Cancer
What this study did
NCT05498389 · Shanghai EpimAb Biotherapeutics Co., Ltd.
2023-06 – 2024-12 · Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, EGFR Mutation-Related Tumors
What this study did
NCT04770688 · Shanghai Chest Hospital
2020-11-19 – 2024-06-20 · Non-Small Cell Lung Cancer With EGFR Mutation, Locally Advanced Solid Tumor, Metastatic Cancer, Adenocarcinoma of Lung
What this study did
NCT05284994 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2022-03-11 – 2024-06 · Nonsmall-cell Lung Cancer
What this study did
NCT04720976 · Allist Pharmaceuticals, Inc.
2021-03-23 – 2023-12-19 · Solid Tumor, NSCLC
What this study did
NCT01802632 · AstraZeneca
2013-03-04 – 2023-12-11 · Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
What this study did
NCT02954523 · Chul Kim
2016-10 – 2023-03-03 · EGFR Gene Mutation, Nonsmall Cell Lung Cancer
What this study did
NCT02803203 · Memorial Sloan Kettering Cancer Center
2016-06-29 – 2022-03-01 · Non-small Cell Lung Cancer, EGFR-mutant Lung Cancers
What this study did
NCT03455829 · G1 Therapeutics, Inc.
2018-03-29 – 2022-02-14 · Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-small Cell Lung Cancer
What this study did
NCT03989115 · Revolution Medicines, Inc.
2019-07-02 – 2022-02-08 · Solid Tumor
What this study did
NCT03450330 · Dizal Pharmaceuticals
2018-04-16 – 2020-01-10 · Nonsmall Cell Lung Cancer
What this study did
Other / comorbidity
NCT06618287 · Bristol-Myers Squibb
2025-02-04 – 2031-02-26 · Lung Cancer, Breast Cancer
What this study did
NCT07153055 · Misty Shields
2027-01 – 2029-10 · Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer
What this study did
NCT07612137 · Innovent Biologics (Suzhou) Co. Ltd.
2026-06-01 – 2028-06-30 · Solid Tumor
What this study did
NCT05785741 · DualityBio Inc.
2023-08-17 – 2028-04-30 · Advanced Solid Tumor
What this study did
Phase 1 (62)
Non-Small Cell Lung Cancer
NCT04780568 · Ohio State University Comprehensive Cancer Center
2022-01-18 – 2029-07-31 · Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT05401110 · Karen Reckamp, MD, MS
2023-09-15 – 2029-01 · Non Small Cell Lung Cancer, Lung Cancer
What this study did
NCT07361705 · Alpha Biopharma (Jiangsu) Co., Ltd.
2026-01-31 – 2028-09-15 · Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment
What this study did
NCT06557096 · Second Affiliated Hospital of Nanchang University
2024-08-20 – 2028-07-31 · Non Small Cell Lung Cancer, Circulating Tumor Cell, EGF-R Positive Non-Small Cell Lung Cancer
What this study did
NCT04141644 · University of Utah
2020-08-20 – 2028-04-30 · Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
What this study did
NCT04676477 · Daiichi Sankyo
2021-06-11 – 2027-12-14 · Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT05166616 · City of Hope Medical Center
2022-03-07 – 2027-10-28 · Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
What this study did
NCT05693090 · Kura Oncology, Inc.
2023-02-01 – 2027-07-27 · NSCLC
What this study did
NCT02496663 · National Cancer Institute (NCI)
2016-05-11 – 2027-06-30 · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT07315113 · Nuvectis Pharma, Inc.
2025-12-18 – 2027-06 · EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients
What this study did
NCT02503722 · National Cancer Institute (NCI)
2017-03-23 – 2027-02-28 · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT02143466 · AstraZeneca
2014-08-05 – 2026-12-31 · Advanced Non Small Cell Lung Cancer
What this study did
NCT04762199 · Emory University
2021-02-24 – 2026-12-27 · Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT06067776 · Jonathan Riess
2024-01-01 – 2026-11-01 · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT04772235 · Instituto Oncológico Dr Rosell
2022-02-11 – 2026-06 · Nsclc
What this study did
NCT06362980 · National Cancer Center, China
2024-05-22 – 2026-04-01 · NSCLC
What this study did
NCT04721015 · AbbVie
2021-02-23 – 2026-02 · Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)
What this study did
NCT03810807 · Memorial Sloan Kettering Cancer Center
2019-01-17 – 2025-12-15 · Metastatic Non-small Cell Lung Cancer
What this study did
NCT06525246 · Ono Pharmaceutical Co., Ltd.
2021-08-06 – 2025-06-23 · Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer, EGFR Mutation-Related Tumors
What this study did
NCT04001777 · Ascentage Pharma Group Inc.
2019-07-04 – 2025-05-27 · EGFR Positive Non-small Cell Lung Cancer
What this study did
NCT04862780 · Blueprint Medicines Corporation
2021-06-29 – 2024-10-07 · Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, EGFR T790M, EGFR C797S, EGFR L858R, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, EGFR Exon 19 Deletion, EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance, EGFR Activating Mutation, Protein Kinase Inhibitors, Antineoplastic Agents, Thoracic Neoplasms
What this study did
NCT02197234 · AstraZeneca
2014-12-22 – 2024-06-03 · Non Small Cell Lung Cancer
What this study did
NCT05489731 · Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.
2022-09-21 – 2024-04-24 · Advanced Non-small Cell Lung Cancer
What this study did
NCT06032936 · LianBio LLC
2023-07-27 – 2024-03-29 · NSCLC
What this study did
NCT02520778 · National Cancer Institute (NCI)
2016-08-30 – 2023-12-04 · Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT04479306 · M.D. Anderson Cancer Center
2020-06-18 – 2023-07-27 · Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT04959981 · Erasca, Inc.
2021-09-02 – 2023-04-27 · Advanced Non-squamous Non-small-cell Lung Cancer
What this study did
NCT02163733 · AstraZeneca
2014-11-14 – 2023-01-24 · Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
What this study did
NCT05153408 · Blueprint Medicines Corporation
2022-01-13 – 2022-12-09 · Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, EGFR C797S, EGFR C797A, EGFR L858R, EGFR Exon 19 Deletion, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance, EGFR Activating Mutation, Thoracic Neoplasms, Antineoplastic Agents, Protein Kinase Inhibitors, EGFR C797G, EGFR C797X, Non Small Cell Lung Cancer
What this study did
NCT02908750 · AstraZeneca
2017-03-02 – 2022-10-11 · Non Small Cell Lung Cancer
What this study did
NCT04448379 · Shanghai JMT-Bio Inc.
2020-06-29 – 2022-06-30 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
NCT04541407 · University of Colorado, Denver
2020-10-29 – 2022-06-07 · Non Small Cell Lung Cancer, CNS Progression
What this study did
NCT02789345 · Eli Lilly and Company
2016-10-24 – 2022-05-09 · Non-small Cell Lung Cancer
What this study did
NCT03535363 · Case Comprehensive Cancer Center
2018-10-26 – 2022-04-01 · NSCLC, Non-small Cell Lung Cancer
What this study did
NCT03858491 · Academisch Ziekenhuis Maastricht
2020-11-01 – 2021-12-31 · Non Small Cell Lung Cancer
What this study did
NCT02197247 · AstraZeneca
2014-12-04 – 2021-05-26 · Non Small Cell Lung Cancer
What this study did
NCT02228369 · AstraZeneca
2014-11-05 – 2020-10-28 · EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
What this study did
NCT03463525 · AstraZeneca
2018-10-24 – 2020-10-05 · Non-small Cell Lung Cancer
What this study did
NCT03255083 · Daiichi Sankyo
2019-04-10 – 2020-09-04 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT03418532 · Molecular Partners AG
2018-03-22 – 2020-04-24 · EGFR-mutated NSCLC (Disorder)
What this study did
NCT03050411 · Peking University Third Hospital
2016-05 – 2019-10 · Nonsmall Cell Lung Cancer
What this study did
NCT02529995 · AstraZeneca
2015-08-24 – 2019-09-27 · Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive
What this study did
NCT02317016 · AstraZeneca
2015-03-10 – 2018-05-22 · Non Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT05647122 · AstraZeneca
2022-12-21 – 2028-08-03 · Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
What this study did
NCT03567642 · Memorial Sloan Kettering Cancer Center
2018-06-12 – 2027-06 · Lung Cancer
What this study did
NCT06507306 · Kumquat Biosciences Inc.
2024-06-03 – 2027-01-31 · Solid Tumor, Adult
What this study did
NCT02099058 · AbbVie
2014-01-15 – 2026-08 · Advanced Solid Tumors Cancer
What this study did
Phase 4 (7)
Non-Small Cell Lung Cancer
NCT07279935 · AstraZeneca
2026-05-26 – 2030-05-18 · Non-small Cell Lung Cancer
What this study did
NCT05748093 · Maastricht University Medical Center
2024-04-01 – 2027-09-01 · Non-small Cell Lung Cancer
What this study did
NCT04413201 · Michael Hopp
2020-09-11 – 2026-12-31 · Non-squamous NSCLC
What this study did
NCT05785208 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2022-06-28 – 2025-10-31 · Non Small Cell Lung Cancer
What this study did
NCT05219162 · AstraZeneca
2022-02-25 – 2024-04-29 · Advanced NSCLC
What this study did
NCT03853551 · AstraZeneca
2019-04-18 – 2020-04-15 · Non Small Cell Lung Cancer (NSCLC)
What this study did
Other / comorbidity
NCT06824792 · NING LI
2025-03-01 – 2030-02-28 · Advanced Solid Tumors
What this study did
Early phase / not applicable (8)
Non-Small Cell Lung Cancer
NCT06709274 · Guangdong Association of Clinical Trials
2024-11 – 2032-01 · Non-Small Cell Lung Cancer
What this study did
NCT06053099 · Intergroupe Francophone de Cancerologie Thoracique
2024-01-22 – 2031-10 · Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R
What this study did
NCT05998993 · Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
2023-11 – 2028-11 · EGF-R Positive Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer, EGFR Exon 19 Deletion, EGFR Exon 21 Mutation, EGFR G719X
What this study did
NCT05033691 · Hadassah Medical Organization
2021-03-09 – 2026-12-31 · NSCLC, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Brain Metastases
What this study did
NCT03969823 · Seoul National University Hospital
2019-05-23 – 2026-12-31 · Locally Advanced or Metastatic NSCLC
What this study did
NCT05583409 · Li Zhang
2023-01-01 – 2025-12-30 · Stage IV Non-small Cell Lung Cancer
What this study did
NCT04737382 · The Netherlands Cancer Institute
2019-08-22 – 2024-08-22 · Non-small-cell Lung Carcinoma
What this study did
Used as active comparator (16)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (7)
Non-Small Cell Lung Cancer
NCT07897188 · Jiangsu Aosaikang Pharmaceutical Co., Ltd.
2026-10-30 – 2032-11-20 · EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive
What this study did
NCT04487080 · Janssen Research & Development, LLC
2020-09-30 – 2028-02-16 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT05382728 · TYK Medicines, Inc
2022-06-08 – 2027-12 · NSCLC, EGFR Activating Mutation
What this study did
NCT04035486 · AstraZeneca
2019-07-02 – 2027-09-30 · Non-Small Cell Lung Cancer
What this study did
NCT04870190 · Shanghai Chest Hospital
2021-06-01 – 2024-06-01 · NSCLC
What this study did
NCT05493501 · EQRx International, Inc.
2022-12-14 – 2023-08-31 · NSCLC
What this study did
Phase 2/3 (1)
Non-Small Cell Lung Cancer
NCT07642024 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-07-24 – 2032-12 · Non-small Cell Lung Cancer
What this study did
Phase 2 (6)
Non-Small Cell Lung Cancer
NCT05948813 · TYK Medicines, Inc
2023-08-17 – 2030-03-30 · NSCLC, EGFR Activating Mutation, Brain Metastases
What this study did
NCT07379476 · Chinese University of Hong Kong
2026-02-11 – 2030-03-03 · Lung Cancer (NSCLC)
What this study did
NCT07229729 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2025-11-24 – 2029-10 · Non-small Cell Lung Cancer
What this study did
NCT06752408 · Peking Union Medical College Hospital
2024-12-17 – 2028-01-16 · Non Small Cell Lung Cancer
What this study did
NCT06574347 · Avistone Biotechnology Co., Ltd.
2024-08-07 – 2027-07-31 · Non-Small-Cell Lung Cancer
What this study did
NCT06319950 · Taizhou Hospital
2024-04-01 – 2026-12-30 · Lung Cancer, Nonsmall Cell
What this study did
Phase 1/2 (2)
Non-Small Cell Lung Cancer
NCT07285148 · Beijing Pearl Biotechnology Limited Liability Company
2026-06 – 2029-12 · Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration
What this study did
NCT07079475 · Dizal Pharmaceuticals
2025-07-30 – 2028-12 · Non-Small Cell Lung Cancer
What this study did
Appears in other studies (20)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (8)
Non-Small Cell Lung Cancer
NCT05624996 · NRG Oncology
2023-07-12 – 2036-10-15 · Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
What this study did
NCT06350097 · AstraZeneca
2024-04-29 – 2031-08-29 · Non-small Cell Lung Cancer
What this study did
NCT07738172 · National Taiwan University Hospital
2026-09-08 – 2031-08-01 · Lung Neoplasms, Non-Small Cell Lung Cancer
What this study did
NCT06838273 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-02-24 – 2028-12 · Non-small Cell Lung Cancer
What this study did
NCT05009836 · Hutchmed
2021-09-06 – 2028-05-30 · Non-small Cell Lung Cancer
What this study did
NCT06670196 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2024-11-27 – 2027-07 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT04181060 · National Cancer Institute (NCI)
2020-12-28 – 2029-06-30 · Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
Phase 2 (9)
Non-Small Cell Lung Cancer
NCT07177092 · Jianxing He
2025-09-08 – 2030-12-01 · Non-Small Cell Lung Cancer, EGFR
What this study did
NCT06452433 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-06-01 – 2028-02-02 · Non-small Cell Lung Cancer
What this study did
NCT06741085 · Memorial Sloan Kettering Cancer Center
2024-12-13 – 2027-12 · Non Small Cell Lung Cancer Metastatic
What this study did
NCT05163249 · Guangdong Association of Clinical Trials
2022-05-31 – 2026-08 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04988607 · Guangdong Association of Clinical Trials
2021-08 – 2025-05 · Lung Cancer
What this study did
NCT03769103 · British Columbia Cancer Agency
2019-03-19 – 2025-04 · Lung Cancer Non-small Cell Stage IV, Brain Metastases
What this study did
NCT03543683 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
2018-01-01 – 2024-06-01 · Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, EGFR T790M
What this study did
NCT04184921 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
2019-01-01 – 2024-06-01 · Lung Cancer Non-small Cell Stage IV
What this study did
NCT03133546 · ETOP IBCSG Partners Foundation
2017-05-31 – 2024-02-29 · Non Small Cell Lung Cancer Metastatic
What this study did
Phase 1/2 (1)
Non-Small Cell Lung Cancer
NCT06071013 · China Medical University Hospital
2024-02-23 – 2026-08-27 · Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation
What this study did
Phase 1 (1)
Non-Small Cell Lung Cancer
NCT07271446 · Precision Biotech Taiwan Corp.
2018-09-01 – 2023-12-01 · Non-small Cell Lung Cancer
What this study did
Early phase / not applicable (1)

Competitive landscape

This mechanism is crowded: 41 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Osimertinib (Tagrisso): this drugApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
Cetuximab
Approved(overall)
Monoclonal antibodyEGFR
Partial signal(overall)
No reviewed efficacy summary in this indication
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Aglatimagene BesadenovecPhase 3Gene therapy / editingHerpes simplex virus thymidine kinase (HSV-tk) gene productnot yet gradedNo reviewed efficacy summary in this indication
AlmonertinibPhase 3Small moleculeEGFRPartial signal
NCT04500717: ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205).
AndamertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
ApatinibPhase 3Small moleculeVEGFR2Partial signal
NCT01270386: Primary (PFS): median 4.7 vs 1.9 months, apatinib vs placebo, significantly improved; ORR 12.2% vs 0%; DCR 69% vs 24%.
AsandeutertinibPhase 3Small moleculeEGFRWeak signal
NCT05146219: Confirmed investigator-assessed intracranial ORR 93.1% (95% CI: 77.2%-99.2%) in 29 patients at 160 mg once daily; median PFS 13.5 months
BecotatugPhase 3Monoclonal antibodyEGFRPartial signal
NCT06380348: Primary endpoint, IRC-assessed progression-free survival vs platinum-pemetrexed: met at a prespecified interim analysis (2026-09-24).
BefotertinibPhase 3Small moleculeEGFRPartial signal
NCT04206072: Median IRC-assessed PFS: 22.1 months (befotertinib) vs 13.8 months (icotinib); HR 0.49 (95% CI 0.36-0.68), P<0.0001
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
FHND9041Phase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
FurmonertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
IcotinibPhase 3Small moleculeEGFRPartial signal
NCT01719536: Primary endpoint, PFS (CONVINCE trial): icotinib 11.2 months vs cisplatin/pemetrexed+pemetrexed maintenance 7.9 months; HR 0.61 (95% CI 0.43-0.87), p=0.006
NCT01040780: Progression Free Survival (2-7 months): Icotinib 4.6 months (95% CI 3.5 to 6.3) vs Gefitinib 3.4 months (95% CI 2.3 to 3.8)
LimertinibPhase 3Small moleculeEGFR, EGFR T790M (resistant mutant, selective over wild-type EGFR)Reliable signal
NCT04143607: NCT04143607 (limertinib/ASK120067 vs gefitinib first-line trial), primary endpoint median PFS: limertinib 20.7 months vs gefitinib 9.7 months; HR 0.44
PruvonertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
RezivertinibPhase 3Small moleculeEGFRReliable signal
NCT03866499: REZOR (NCT03866499), primary endpoint median PFS: rezivertinib (BPI-7711) 19.3 months vs gefitinib 9.6 months; HR 0.48 (95% CI 0.36-0.63); p<0.0001
NCT03812809: ORR by blinded independent central review 64.6% (95% CI 58.0%-70.8%)
Rilertinib (SH-1028)Phase 3Small moleculeEGFRReliable signal
NCT04239833: Median PFS: 19.3 months (rilertinib/SH-1028) vs 9.8 months (gefitinib), HR 0.46, P<0.0001 -- primary endpoint met.
ZipalertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
PimurutamabPhase 2/3Monoclonal antibodyEGFRnot yet gradedNo reviewed efficacy summary in this indication
ZorifertinibPhase 2/3Small moleculeEGFRPartial signal
NCT03653546: Median PFS by blinded independent central review: 9.6 months (zorifertinib/AZD3759) vs 6.9 months (control, gefitinib or erlotinib); HR 0.719 (95% CI 0.580-0.893), p=0.0024
BEBT-109Phase 2Small moleculeEGFRWeak signalNo reviewed efficacy summary in this indication
JS111Phase 2Small moleculeEGFRWeak signalNo reviewed efficacy summary in this indication
SutetinibPhase 2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
ANS02Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
BBT-207Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
BH-30643Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
BPI-361175Phase 1/2Small moleculeEGFRWeak signalNo reviewed efficacy summary in this indication
Dositinib MesylatePhase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
DZD6008Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
H002Phase 1/2Small moleculeEGFRWeak signalNo reviewed efficacy summary in this indication
JIN-A02Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
PH009-1Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
SilevertinibPhase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
STX-241Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
VRN110755Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
ALX2004Phase 1Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
AST2303Phase 1Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
EPI-326Phase 1Multispecific antibodyEGFRnot yet gradedNo reviewed efficacy summary in this indication
HLX42Phase 1Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
HSK40118Phase 1Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 101 furthest-along competitors are listed; 510 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(86 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tagrisso (Osimertinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (13)
November 2026 (2)
Early phase / not applicableNon-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-11 · NCT05998993 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-11-30 · NCT07256509 · CT.gov ↗
What to watch
December 2026 (11)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT07315113 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03909334 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-02 · NCT04285671 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-12 · NCT07376382 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-24 · NCT04322890 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-27 · NCT04762199 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-30 · NCT06109558 · CT.gov ↗
What to watch
Phase 1Solid Tumor, AdultActive not recruiting
Est. primary completion 2026-12-31 · NCT06507306 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT04780568 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT07322783 · CT.gov ↗
What to watch
Phase 4Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT04413201 · CT.gov ↗
What to watch
2027 (36)
January 2027 (2)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01-11 · NCT06417814 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01-31 · NCT04743505 · CT.gov ↗
What to watch
February 2027 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02-01 · NCT07323641 · CT.gov ↗
What to watch
Phase 3CancerActive not recruiting
Est. primary completion 2027-02-22 · NCT05629234 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-02-28 · NCT02503722 · CT.gov ↗
What to watch
March 2027 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-03-09 · NCT06014827 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-03-26 · NCT06380348 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-04-01 · NCT03410043 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05 · NCT04410796 · CT.gov ↗
What to watch
June 2027 (9)
Phase 1Lung CancerActive not recruiting
Est. primary completion 2027-06 · NCT03567642 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT07485452 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06 · NCT06498986 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT06557096 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT02496663 · CT.gov ↗
What to watch
Phase 1/2Solid TumorNot yet recruiting
Est. primary completion 2027-06-30 · NCT07612137 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT05642572 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT03191149 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT03392246 · CT.gov ↗
What to watch
July 2027 (3)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-07 · NCT05880706 · CT.gov ↗
What to watch
Phase 4Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-07-01 · NCT05748093 · CT.gov ↗
What to watch
Phase 2Advanced Solid Tumors Which Are cMET-dependentActive not recruiting
Est. primary completion 2027-07-30 · NCT03040973 · CT.gov ↗
What to watch
August 2027 (3)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-08-02 · NCT05120349 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-30 · NCT07669779 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-31 · NCT07329322 · CT.gov ↗
What to watch
September 2027 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-09-01 · NCT05528458 · CT.gov ↗
What to watch
Phase 2Lung CancerRecruiting
Est. primary completion 2027-09-01 · NCT04591002 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT03667820 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-10-01 · NCT05801029 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-10-28 · NCT05166616 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-11-30 · NCT06142617 · CT.gov ↗
What to watch
December 2027 (6)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07038460 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2027-12-30 · NCT05785741 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07603791 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT06918782 · CT.gov ↗
What to watch
Phase 2Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma …Active not recruiting
Est. primary completion 2027-12-31 · NCT02465060 · CT.gov ↗
What to watch
2028 (17)
January 2028 (2)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01 · NCT05401110 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01-01 · NCT07505173 · CT.gov ↗
What to watch
February 2028 (3)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-02-15 · NCT06829459 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-02-28 · NCT03586453 · CT.gov ↗
What to watch
Phase 4Advanced Solid TumorsNot yet recruiting
Est. primary completion 2028-02-29 · NCT06824792 · CT.gov ↗
What to watch
March 2028 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03 · NCT04486833 · CT.gov ↗
What to watch
April 2028 (3)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-04 · NCT07535437 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-04-10 · NCT06712680 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-04-23 · NCT07361705 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-30 · NCT07375316 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-09 · NCT06486142 · CT.gov ↗
What to watch
October 2028 (3)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10-14 · NCT07206498 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10-30 · NCT07911449 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-10-31 · NCT03833154 · CT.gov ↗
What to watch
December 2028 (3)
Phase 2Advanced Solid TumorsRecruiting
Est. primary completion 2028-12 · NCT06895928 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-31 · NCT07622186 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT06908772 · CT.gov ↗
What to watch
2029 (11)
January 2029 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-01 · NCT06206850 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-01 · NCT06709274 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-01-24 · NCT07058519 · CT.gov ↗
What to watch
April 2029 (1)
Phase 1/2Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung CancerRecruiting
Est. primary completion 2029-04 · NCT07153055 · CT.gov ↗
What to watch
May 2029 (2)
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-05-15 · NCT07486648 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-05-30 · NCT07295821 · CT.gov ↗
What to watch
June 2029 (2)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-06 · NCT06436144 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-06-30 · NCT05546866 · CT.gov ↗
What to watch
November 2029 (2)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-11-02 · NCT04665206 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-11-22 · NCT05526755 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07710612 · CT.gov ↗
What to watch
2030 (5)
February 2030 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-02 · NCT05142189 · CT.gov ↗
What to watch
May 2030 (1)
Phase 4Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-05-18 · NCT07279935 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-06-30 · NCT07073365 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-09 · NCT07155187 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-12 · NCT07874490 · CT.gov ↗
What to watch
2031 (3)
February 2031 (1)
Phase 1/2Lung Cancer, Breast CancerRecruiting
Est. primary completion 2031-02-26 · NCT06618287 · CT.gov ↗
What to watch
October 2031 (1)
Early phase / not applicableNon-Small Cell Lung CancerRecruiting
Est. primary completion 2031-10 · NCT06053099 · CT.gov ↗
What to watch
December 2031 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-12-30 · NCT07680790 · CT.gov ↗
What to watch
2036 (1)
November 2036 (1)
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2036-11 · NCT07005102 · CT.gov ↗
What to watch

See the full readout calendar ↗